デジタルパソロジー市場 – 2030年までの世界予測

本レポートは、製品、タイプ、用途、エンドユーザー、地域に基づいてデジタルパソロジー市場を分析しています。また、市場の成長に影響を与える要因（推進要因、機会、課題など）も分析しています。ステークホルダーにとっての市場機会と課題を評価し、市場リーダーの競争環境の詳細を提供します。さらに、ミクロ市場の成長傾向、見通し、そしてデジタルパソロジー市場全体への貢献についても調査しています。さらに、5つの主要地域における市場セグメントの収益予測も提供しています。

The market for digital pathology is segmented into three categories based on type: scanners, storage systems, and software. Given the significance of these devices in the digital pathology workflow, the scanners segment accounted for the largest share of the product category in 2024. Scanners are critical in enabling pathologists to view and analyze tissue samples on computer screens, as scanners convert physical glass slides to high-resolution digital images. The development of diagnostic remote access is paramount for improved accessibility and efficiency of pathology services by allowing pathologists to evaluate cases from any physical location, hence, the demand for scanners. The advancements in scanner technology, such as improved scanning rates and greater resolution imaging, have led to increased workflow, improved diagnostic accuracy, and value for investment for laboratories or medical facilities.

デジタルパソロジーの市場は、タイプに基づいてスキャナー、ストレージシステム、およびソフトウェアの3つのカテゴリに分類されます。デジタルパソロジーのワークフローにおけるこれらのデバイスの重要性を考えると、スキャナーセグメントは2024年に製品カテゴリで最大のシェアを占めました。スキャナーは、物理的なガラススライドを高解像度のデジタル画像に変換するため、病理学者がコンピューター画面で組織サンプルを表示および分析できるようにするために不可欠です。診断リモートアクセスの開発は、病理学者が物理的な場所から症例を評価できるようにすることで、病理学サービスのアクセス性と効率性を向上させるために最も重要であり、これがスキャナーの需要です。スキャン速度の向上や画像解像度の向上などのスキャナー技術の進歩は、ワークフローの増加、診断精度の向上、および研究室や医療施設の投資価値につながっています。

By type, the human pathology segment is expected to hold the largest share during the forecast period.

The human pathology segment is expected to occupy the largest share of the digital pathology market throughout the forecast period largely due to the rising global burden of complex and chronic diseases, including cancer, cardiovascular diseases, and infections, which demand timely and accurate diagnostic outcomes.

Digital pathology, examination, and diagnosis, typically performed under the eyepiece of a microscope, are advantageous in many aspects, such as producing high-resolution images, providing automated analytics, allowing for image storage, cloud storage, and telepathology slide-sharing services. Equally important is the unparalleled advantage of being able to provide remote consultation that may involve co-consultation and coordination at various sites and second opinions from specialists.

Furthermore, digital pathology is quickly being adopted and evolving to integrate the newest technologies such as artificial intelligence (AI), machine learning (ML), deep learning image recognition, which are all improving diagnostic accuracy, decreasing turnaround time, and even aiding in recognizing subtle histological patterns, which makes digital pathology a foundational element of practice in laboratories and hospitals around the world.

North America is expected to lead the global digital pathology market during the forecast period.

North America led the digital pathology market in 2024 due to a mature healthcare system and large financial investments toward developing healthcare technology. The regulatory environment in North America—especially in the US and Canada—supports a relatively faster review and approval process for emerging digital pathology technologies. This, combined with growing awareness among healthcare providers and rising demand for advanced diagnostic solutions, has driven strong adoption of digital pathology across the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level (35%), Director-level (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East & Africa (5%)

List of Companies Profiled in the Report

Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US),  Indica Labs Inc. (US),  Objective Pathology Services Limited (Canada),  Sectra AB (Sweden),  OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland),  Paige AI, Inc. (US),  Fujifilm Holdings Corporation (Japan), Proscia Inc. (US),  KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain)

Research Coverage

This report studies the digital pathology market based on product, type, application, end user, and region. The report also analyses factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total digital pathology market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (Growing adoption of AI-enabled digital pathology, rising burden of cancer, diabetes, and chronic diseases, expansion of digital pathology in drug discovery and biomarker validation, Cancer screening programs in emerging markets), restraints (High initial capital costs, Data interoperability issues with existing lab systems, regulatory and reimbursement uncertainty), opportunities (Affordable scanner development for low-resource settings, growing preference for personalized medicine, government-backed digitization in emerging economies) challenges (Shortage of skilled pathologists and technicians, algorithm validation issues, data security and patient privacy concerns), are contributing the growth of the digital pathology market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market
• Market Development: Comprehensive information about lucrative markets and analysis of the authentication and brand protection market across varied regions
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the digital pathology market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology market

Table of Contents

1               INTRODUCTION              27

1.1           STUDY OBJECTIVES       27

1.2           MARKET DEFINITION   27

1.2.1        INCLUSIONS & EXCLUSIONS       28

1.3           MARKET SCOPE                29

1.3.1        MARKETS COVERED       29

1.3.2        YEARS CONSIDERED      30

1.3.3        CURRENCY CONSIDERED            30

1.4           STAKEHOLDERS               30

1.5           SUMMARY OF CHANGES               31

2               RESEARCH METHODOLOGY       32

2.1           RESEARCH APPROACH  32

2.1.1        SECONDARY DATA          32

2.1.1.1    Key data from secondary sources       34

2.1.2        PRIMARY DATA 34

2.1.2.1    Key data from primary sources           36

2.1.2.2    Key industry insights           36

2.2           RESEARCH METHODOLOGY DESIGN     37

2.3           MARKET SIZE ESTIMATION         38

2.4           MARKET BREAKDOWN AND DATA TRIANGULATION                 43

2.5           RESEARCH ASSUMPTIONS           45

2.6           MARKET ASSUMPTIONS               45

2.6.1        OVERALL STUDY ASSUMPTIONS              45

2.7           RISK ASSESSMENT           46

2.8           RESEARCH LIMITATIONS             46

2.8.1        METHODOLOGY-RELATED LIMITATIONS           46

2.8.2        SCOPE-RELATED LIMITATIONS                 46

3               EXECUTIVE SUMMARY  47

4               PREMIUM INSIGHTS       51

4.1           DIGITAL PATHOLOGY MARKET OVERVIEW        51

4.2           NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER AND COUNTRY (2024)              52

4.3           DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         53

4.4           DIGITAL PATHOLOGY MARKET: REGIONAL MIX                 54

5               MARKET OVERVIEW       55

5.1           INTRODUCTION              55

5.2           MARKET DYNAMICS       55

5.2.1        DRIVERS               55

5.2.1.1    AI-enabled digital pathology improving lab throughput                 55

5.2.1.2    Rising burden of cancer, diabetes, and cardiovascular diseases                 56

5.2.1.3    Expansion of digital pathology in drug discovery and biomarker validation                58

5.2.1.4    National cancer screening programs in emerging markets                 58

5.2.2        RESTRAINTS      59

5.2.2.1    High initial capital cost of digital pathology systems      59

5.2.2.2    Data interoperability issues with existing lab systems    60

5.2.2.3    Regulatory and reimbursement uncertainty     60

5.2.3        OPPORTUNITIES              60

5.2.3.1    Affordable scanner development for low-resource settings                 60

5.2.3.2    Personalized medicine driving precision diagnostics     61

5.2.3.3    Government-backed digitalization in emerging economies                 62

5.2.4        CHALLENGES    62

5.2.4.1    Shortage of skilled pathologists and technicians              62

5.2.4.2    Algorithm validation and trust in AI-based diagnostics 62

5.2.4.3    Data security and privacy concerns   63

5.3           INDUSTRY TRENDS         63

5.3.1        AI-POWERED DIAGNOSTICS GO MAINSTREAM  63

5.3.2        CLOUD-BASED PLATFORMS AND REMOTE ACCESS BECOME CRITICAL ENABLERS   63

5.4           TECHNOLOGY ANALYSIS             64

5.4.1        CLOUD STORAGE & ARCHIVING               64

5.4.2        WHOLE SLIDE IMAGING (WSI) SCANNERS            64

5.4.3        IMAGE MANAGEMENT SYSTEMS               64

5.4.4        ADJACENT TECHNOLOGIES       64

5.4.4.1    Genomic sequencing            64

5.4.4.2    Artificial Intelligence and Machine Learning   65

5.4.5        COMPLEMENTARY TECHNOLOGIES       65

5.4.5.1    LIS & PACS           65

5.5           PRICING ANALYSIS          65

5.5.1        AVERAGE SELLING PRICE TREND, BY REGION   66

5.5.2        AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT           66

5.6           VALUE CHAIN ANALYSIS               66

5.7           ECOSYSTEM ANALYSIS  67

5.8           PORTER’S FIVE FORCES ANALYSIS           69

5.8.1        THREAT OF NEW ENTRANTS      70

5.8.2        THREAT OF SUBSTITUTES          70

5.8.3        BARGAINING POWER OF SUPPLIERS       70

5.8.4        BARGAINING POWER OF BUYERS             70

5.8.5        INTENSITY OF COMPETITIVE RIVALRY 70

5.9           HS CODES           70

5.10         REGULATORY LANDSCAPE         71

5.10.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             71

5.10.2      REGULATORY ANALYSIS               72

5.10.2.1  North America      72

5.10.2.1.1                US           72

5.10.2.1.2                Canada   73

5.10.2.2  Europe   73

5.10.2.3  Asia Pacific            75

5.10.2.3.1                Japan      75

5.10.2.3.2                China      75

5.10.2.3.3                India       76

5.11         PATENT ANALYSIS          76

5.11.1      PATENT PUBLICATION TRENDS               76

5.11.2      JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS    77

5.11.3      MAJOR PATENTS              77

5.12         CASE STUDY ANALYSIS 79

5.13         KEY CONFERENCES & EVENTS, 2025–2026              80

5.14         KEY STAKEHOLDERS & BUYING CRITERIA            81

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           81

5.14.2      BUYING CRITERIA           82

5.14.3      TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS            82

5.15         END-USER ANALYSIS      83

5.15.1      UNMET NEEDS 83

5.15.2      END-USER EXPECTATIONS         84

5.16         BUSINESS MODEL ANALYSIS      84

5.17         INVESTMENT & FUNDING SCENARIO     85

5.18         IMPACT OF AI ON DIGITAL PATHOLOGY MARKET                 85

5.19         IMPACT OF US TARIFF ON DIGITAL PATHOLOGY MARKET               85

5.19.1      INTRODUCTION              85

5.19.2      KEY TARIFF RATES          86

5.20         PRICE IMPACT ANALYSIS             86

5.21         IMPACT ON COUNTRY/REGION                87

5.21.1      US           87

5.21.2      EUROPE               87

5.21.3      ASIA PACIFIC     87

5.21.4      IMPACT ON END-USE INDUSTRIES          87

6               DIGITAL PATHOLOGY MARKET, BY PRODUCT  88

6.1           INTRODUCTION              89

6.2           SCANNERS          89

6.2.1        BRIGHTFIELD SCANNERS             92

6.2.1.1    Cost-efficient features to boost demand           92

6.2.2        FLUORESCENCE SCANNERS        93

6.2.2.1    Ability to detect cellular structures and biomarkers to fuel uptake                 93

6.2.3        OTHER SCANNERS          94

6.3           SOFTWARE         95

6.3.1        INTEGRATED SOFTWARE             97

6.3.1.1    Single & effective suite for multiple applications to propel market                 97

6.3.2        STANDALONE SOFTWARE           98

6.3.2.1    Information management software    99

6.3.2.1.1 Management of image repositories to fuel uptake           99

6.3.2.2    Image analysis software       100

6.3.2.2.1 Ability to automate quantitative evaluation to support market growth    100

6.4           SOFTWARE, BY DEPLOYMENT MODEL  102

6.4.1        CLOUD-BASED MODEL 102

6.4.1.1    Facilitation of collaboration on a single platform to drive market                 102

6.4.2        ON-PREMISE MODEL     104

6.4.2.1    High data security and integration with HCIT solutions to fuel uptake    104

6.4.3        HYBRID MODEL                105

6.4.3.1    Combined flexibility to support market growth               105

6.5           STORAGE SYSTEMS         106

6.5.1        GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET        106

7               DIGITAL PATHOLOGY MARKET, BY TYPE             108

7.1           INTRODUCTION              109

7.2           HUMAN PATHOLOGY    109

7.2.1        INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET             109

7.3           VETERINARY PATHOLOGY          110

7.3.1        IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH     110

8               DIGITAL PATHOLOGY MARKET, BY APPLICATION                 112

8.1           INTRODUCTION              113

8.2           DRUG DISCOVERY           114

8.2.1        INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET               114

8.3           DISEASE DIAGNOSIS      115

8.3.1        INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND      115

8.4           TRAINING & EDUCATION            116

8.4.1        ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH 116

9               DIGITAL PATHOLOGY MARKET, BY END USER  118

9.1           INTRODUCTION              119

9.2           PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 119

9.2.1        INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET               119

9.3           HOSPITALS & REFERENCE LABORATORIES          120

9.3.1        HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND             120

9.4           ACADEMIC & RESEARCH INSTITUTES    122

9.4.1        INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH               122

9.5           DIAGNOSTICS LABORATORIES 123

9.5.1        INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH               123

9.6           VETERINARY LABORATORIES    124

9.6.1        TECHNOLOGICAL ADVANCEMENTS, PARTICULARLY IN WHOLE-SLIDE IMAGING SYSTEMS AND AI-POWERED IMAGE ANALYSIS SOFTWARE, SUPPORT MARKET GROWTH       124

10            DIGITAL PATHOLOGY MARKET, BY REGION       126

10.1         INTRODUCTION              127

10.2         NORTH AMERICA             127

10.2.1      NORTH AMERICA: MACROECONOMIC OUTLOOK                 128

10.2.2      US           132

10.2.2.1  Favorable reimbursements for diagnostics to drive market                 132

10.2.3      CANADA               135

10.2.3.1  Growing awareness on early cancer detection & diagnosis to drive market    135

10.3         EUROPE               139

10.3.1      EUROPE: MACROECONOMIC OUTLOOK               139

10.3.2      GERMANY           143

10.3.2.1  High healthcare expenditure and supportive research initiatives to drive market      143

10.3.3      UK          146

10.3.3.1  Government funding investments for pathology services to fuel market    146

10.3.4      SWEDEN              149

10.3.4.1  Increasing prevalence of chronic diseases to support market growth    149

10.3.5      FRANCE                152

10.3.5.1  Increasing government funding and favorable insurance system to drive adoption  152

10.3.6      SPAIN    154

10.3.6.1  Supportive collaborations among leading companies and hospitals to boost demand  154

10.3.7      ITALY    156

10.3.7.1  Integration of AI & ML to support market growth          156

10.3.8      REST OF EUROPE             158

10.4         ASIA PACIFIC     160

10.4.1      ASIA PACIFIC: MACROECONOMIC OUTLOOK     160

10.4.2      CHINA  166

10.4.2.1  Increasing establishment of hospitals and reference laboratories to drive market      166

10.4.3      JAPAN   168

10.4.3.1  Advanced healthcare infrastructure to support market growth                 168

10.4.4      INDIA    171

10.4.4.1  Growth in pharmaceutical industry to propel market     171

10.4.5      REST OF ASIA PACIFIC   174

10.5         LATIN AMERICA                176

10.5.1      LATIN AMERICA: MACROECONOMIC OUTLOOK                 176

10.5.2      BRAZIL 180

10.5.2.1  High adoption of POC testing to drive market                180

10.5.3      MEXICO                182

10.5.3.1  Growth in companion diagnostics to fuel uptake            182

10.5.4      REST OF LATIN AMERICA             184

10.6         MIDDLE EAST & AFRICA                186

10.6.1      IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH              186

10.6.2      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 187

10.6.3      GCC COUNTRIES              190

10.6.4      REST OF MIDDLE EAST & AFRICA             192

11            COMPETITIVE LANDSCAPE         195

11.1         OVERVIEW          195

11.2         KEY PLAYER STRATEGY/RIGHT TO WIN                195

11.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET                195

11.3         REVENUE ANALYSIS       197

11.4         MARKET SHARE ANALYSIS           197

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 200

11.5.1      STARS   200

11.5.2      EMERGING LEADERS     200

11.5.3      PERVASIVE PLAYERS      200

11.5.4      PARTICIPANTS 201

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         202

11.5.5.1  Company footprint               202

11.5.5.2  Product footprint  203

11.5.5.3  Application footprint            204

11.5.5.4  End-user footprint                205

11.5.5.5  Region footprint   206

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        207

11.6.1      PROGRESSIVE COMPANIES         207

11.6.2      RESPONSIVE COMPANIES            207

11.6.3      DYNAMIC COMPANIES  207

11.6.4      STARTING BLOCKS         207

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 209

11.7         COMPANY VALUATION AND FINANCIAL METRICS                 211

11.8         BRAND/SOFTWARE COMPARATIVE ANALYSIS   212

11.9         COMPETITIVE SCENARIO             213

11.9.1      PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS        213

11.9.2      DEALS  214

11.9.3      OTHER DEVELOPMENTS              214

12            COMPANY PROFILES      215

12.1         KEY COMPANIES              215

12.1.1      DANAHER CORPORATION           215

12.1.1.1  Business overview 215

12.1.1.2  Products offered   216

12.1.1.3  Recent developments           217

12.1.1.3.1                Deals      217

12.1.1.4  MnM view              217

12.1.1.4.1                Key strengths        217

12.1.1.4.2                Strategic choices   217

12.1.1.4.3                Weaknesses and competitive threats 217

12.1.2      HOFFMANN-LA ROCHE LTD.      218

12.1.2.1  Business overview 218

12.1.2.2  Products offered   219

12.1.2.3  Recent developments           220

12.1.2.3.1                Product launches & approvals            220

12.1.2.3.2                Deals      220

12.1.2.4  MnM view              221

12.1.2.4.1                Key strengths        221

12.1.2.4.2                Strategic choices   221

12.1.2.4.3                Weaknesses and competitive threats 221

12.1.3      SECTRA AB         222

12.1.3.1  Business overview 222

12.1.3.2  Products offered   223

12.1.3.3  Recent developments           224

12.1.3.3.1                Deals      224

12.1.3.3.2                Other developments             226

12.1.3.4  MnM view              226

12.1.3.4.1                Key strengths        226

12.1.3.4.2                Strategic choices   226

12.1.3.4.3                Weaknesses and competitive threats 226

12.1.4      HAMAMATSU PHOTONICS K.K. 227

12.1.4.1  Business overview 227

12.1.4.2  Products offered   228

12.1.4.3  Recent developments           229

12.1.4.3.1                Product approvals 229

12.1.4.3.2                Deals      229

12.1.4.4  MnM view              230

12.1.4.4.1                Key strengths        230

12.1.4.4.2                Strategic choices   230

12.1.4.4.3                Weaknesses and competitive threats 230

12.1.5      KONINKLIJKE PHILIPS N.V.          231

12.1.5.1  Business overview 231

12.1.5.2  Products offered   232

12.1.5.3  Recent developments           233

12.1.5.3.1                Product launches & approvals            233

12.1.5.3.2                Deals      233

12.1.5.4  MnM view              234

12.1.5.4.1                Key strengths        234

12.1.5.4.2                Strategic choices   234

12.1.5.4.3                Weaknesses and competitive threats 234

12.1.6      AKOYA BIOSCIENCES, INC.          235

12.1.6.1  Business overview 235

12.1.6.2  Products offered   236

12.1.6.3  Recent developments           237

12.1.6.3.1                Product launches & approvals            237

12.1.7      FUJIFILM HOLDINGS CORPORATION     238

12.1.7.1  Business overview 238

12.1.7.2  Products offered   239

12.1.7.3  Recent developments           240

12.1.7.3.1                Deals      240

12.1.8      HOLOGIC, INC. 241

12.1.8.1  Business overview 241

12.1.8.2  Products offered   242

12.1.8.3  Recent developments           243

12.1.8.3.1                Product approvals 243

12.1.9      3DHISTECH LTD.              244

12.1.9.1  Business overview 244

12.1.9.2  Products offered   244

12.1.9.3  Recent developments           245

12.1.9.3.1                Product launches & enhancements    245

12.1.9.3.2                Other developments             246

12.1.10   APOLLO ENTERPRISE IMAGING CORP.  247

12.1.10.1                 Business overview 247

12.1.10.2                 Products offered   247

12.1.10.3                 Recent developments           248

12.1.10.3.1             Product enhancements        248

12.1.10.3.2             Deals      248

12.1.11   XIFIN, INC.          249

12.1.11.1                 Business overview 249

12.1.11.2                 Products offered   249

12.1.11.3                 Recent developments           249

12.1.11.3.1             Product launches  249

12.1.11.3.2             Deals      250

12.1.12   HURON DIGITAL PATHOLOGY  251

12.1.12.1                 Business overview 251

12.1.12.2                 Products offered   251

12.1.12.2.1             Deals      252

12.1.13   INDICA LABS      253

12.1.13.1                 Business overview 253

12.1.13.2                 Products offered   253

12.1.13.3                 Recent developments           254

12.1.13.3.1             Product launches & approvals            254

12.1.13.3.2             Deals      254

12.1.14   OPTRASCAN, INC.            256

12.1.14.1                 Business overview 256

12.1.14.2                 Products offered   256

12.1.14.3                 Recent developments           257

12.1.14.3.1             Product launches & approvals            257

12.1.14.3.2             Deals      257

12.1.15   GLENCOE SOFTWARE, INC.         258

12.1.15.1                 Business overview 258

12.1.15.2                 Products offered   258

12.1.15.3                 Recent developments           259

12.1.15.3.1             Product enhancements        259

12.1.16   AIFORIA TECHNOLOGIES OY     260

12.1.16.1                 Business overview 260

12.1.16.2                 Products offered   260

12.1.16.3                 Recent developments           261

12.1.16.3.1             Deals      261

12.1.17   PAIGE AI, INC.   262

12.1.17.1                 Business overview 262

12.1.17.2                 Products offered   262

12.1.17.3                 Recent developments           263

12.1.17.3.1             Product launches & enhancements    263

12.1.17.3.2             Deals      263

12.1.18   PROSCIA, INC.   265

12.1.18.1                 Business overview 265

12.1.18.2                 Products offered   265

12.1.18.3                 Recent developments           266

12.1.18.3.1             Product enhancements & approvals  266

12.1.18.3.2             Deals      266

12.2         OTHER PLAYERS              268

12.2.1      QUEST DIAGNOSTICS   268

12.2.2      KONFOONG BIOTECH INTERNATIONAL CO., LTD.                 269

12.2.3      MIKROSCAN TECHNOLOGIES, INC.         270

12.2.4      MOTIC DIGITAL PATHOLOGY   271

12.2.5      KANTERON SYSTEMS     272

12.2.6      MORPHLE LABS INC.      272

12.2.7      EW HEALTHCARE PARTNERS     273

13            APPENDIX           274

13.1         DISCUSSION GUIDE        274

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                279

13.3         CUSTOMIZATION OPTIONS        281

13.4         RELATED REPORTS         281

13.5         AUTHOR DETAILS           282

LIST OF TABLES

TABLE 1                FACTOR ANALYSIS          41

TABLE 2                RISK ASSESSMENT ANALYSIS      46

TABLE 3                INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)                57

TABLE 4                AVERAGE SELLING PRICE TREND OF DIGITAL PATHOLOGY PRODUCTS, BY REGION    66

TABLE 5                AVERAGE SELLING PRICE OF DIGITAL PATHOLOGY PRODUCTS             66

TABLE 6                DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES                69

TABLE 7                REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           71

TABLE 8                US FDA: MEDICAL DEVICE CLASSIFICATION                 72

TABLE 9                US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              72

TABLE 10              CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS      73

TABLE 11              EUROPE: CLASSIFICATION OF IVD DEVICES                 74

TABLE 12              JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA   75

TABLE 13              CHINA: CLASSIFICATION OF MEDICAL DEVICES                 76

TABLE 14              LIST OF PATENTS/PATENT APPLICATIONS                 78

TABLE 15              CASE STUDY 1: ASSESSING IMAGE QUALITY: A COMPARATIVE MULTI-ASSESSMENT EVALUATION OF APERIO GT 450 DX            79

TABLE 16              CASE STUDY 2: HOW TO PROMOTE PATHOLOGY WORKFLOW EFFICIENCY 79

TABLE 17              CASE STUDY 3: ARTIFICIAL INTELLIGENCE IN DIGITAL PATHOLOGY  80

TABLE 18              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY PRODUCTS             81

TABLE 19              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY, BY PRODUCT        81

TABLE 20              KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS             82

TABLE 21              UNMET NEEDS IN DIGITAL PATHOLOGY MARKET               83

TABLE 22              END-USER EXPECTATIONS IN DIGITAL PATHOLOGY MARKET  84

TABLE 23              US-ADJUSTED RECIPROCAL TARIFF RATES                 86

TABLE 24              DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            89

TABLE 25              SCANNING MAGNIFICATION AND APPLICATIONS 89

TABLE 26              DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS  90

TABLE 27              DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            91

TABLE 28              DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY REGION,

2023–2030 (USD MILLION)            91

TABLE 29              BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS           92

TABLE 30              BRIGHTFIELD SCANNERS MARKET, BY REGION, 2023–2030 (USD MILLION)            93

TABLE 31              FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS           93

TABLE 32              FLUORESCENCE SCANNERS MARKET, BY REGION, 2023–2030 (USD MILLION)          94

TABLE 33              OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS              94

TABLE 34              OTHER SCANNERS MARKET, BY REGION, 2023–2030 (USD MILLION)       95

TABLE 35              DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS  96

TABLE 36             DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            96

TABLE 37             DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY REGION,

2023–2030 (USD MILLION)            97

TABLE 38              INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS           98

TABLE 39              INTEGRATED SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)            98

TABLE 40              STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            99

TABLE 41             STANDALONE SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)            99

TABLE 42              INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS       100

TABLE 43              INFORMATION MANAGEMENT SOFTWARE MARKET, BY REGION,

2023–2030 (USD MILLION)            100

TABLE 44              IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS           101

TABLE 45              IMAGE ANALYSIS SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)          101

TABLE 46             DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL,

2023–2030 (USD MILLION)            102

TABLE 47              CLOUD-BASED SOFTWARE OFFERED BY KEY MARKET PLAYERS           103

TABLE 48              CLOUD-BASED MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)            103

TABLE 49              ON-PREMISE SOFTWARE OFFERED BY KEY MARKET PLAYERS           104

TABLE 50              ON-PREMISE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)            105

TABLE 51              HYBRID SOFTWARE OFFERED BY KEY MARKET PLAYERS              105

TABLE 52              HYBRID MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 106

TABLE 53              STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS              107

TABLE 54              DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY REGION,

2023–2030 (USD MILLION)            107

TABLE 55              DIGITAL PATHOLOGY MARKET, BY TYPE, 2023–2030 (USD MILLION)       109

TABLE 56              HUMAN DIGITAL PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)          110

TABLE 57              VETERINARY DIGITAL PATHOLOGY MARKET, BY REGION,

2023–2030 (USD MILLION)            111

TABLE 58              DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              113

TABLE 59              SOFTWARE IMPACT ANALYSIS, BY APPLICATION   113

TABLE 60              DIGITAL PATHOLOGY APPLICATIONS IN DRUG DISCOVERY        114

TABLE 61              DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY REGION,

2023–2030 (USD MILLION)            115

TABLE 62              DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY REGION,

2023–2030 (USD MILLION)            116

TABLE 63              DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY REGION,

2023–2030 (USD MILLION)            117

TABLE 64              DIGITAL PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)            119

TABLE 65              DIGITAL PATHOLOGY MARKET: SOFTWARE IMPACT ANALYSIS, BY END USER             119

TABLE 66              DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          120

TABLE 67              DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS, BY HOSPITAL          121

TABLE 68              DIGITAL PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES,

BY REGION, 2023–2030 (USD MILLION)   122

TABLE 69              DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY REGION, 2023–2030 (USD MILLION)   123

TABLE 70              DIGITAL PATHOLOGY MARKET FOR DIAGNOSTICS LABORATORIES, BY REGION, 2023–2030 (USD MILLION)            124

TABLE 71              DIGITAL PATHOLOGY MARKET FOR VETERINARY LABORATORIES, BY REGION, 2023–2030 (USD MILLION)            125

TABLE 72              DIGITAL PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)            127

TABLE 73              NORTH AMERICA: MACROECONOMIC OUTLOOK, 2024                 128

TABLE 74              NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            129

TABLE 75              NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            130

TABLE 76              NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            130

TABLE 77              NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            130

TABLE 78              NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            131

TABLE 79              NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 131

TABLE 80              NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE,

2023–2030 (USD MILLION)            131

TABLE 81              NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            132

TABLE 82              NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            132

TABLE 83              US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 133

TABLE 84              US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     133

TABLE 85              US: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            134

TABLE 86              US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            134

TABLE 87              US: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                134

TABLE 88              US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            135

TABLE 89              CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040          136

TABLE 90              CANADA: FUNDING INITIATIVES FOR DIGITAL PATHOLOGY     136

TABLE 91              CANADA: KEY MACROINDICATORS         137

TABLE 92              CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     137

TABLE 93              CANADA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            137

TABLE 94              CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            138

TABLE 95              CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)         138

TABLE 96              CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            138

TABLE 97              EUROPE: MACROECONOMIC OUTLOOK                 139

TABLE 98              EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     140

TABLE 99              EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     140

TABLE 100            EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            140

TABLE 101            EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            141

TABLE 102            EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            141

TABLE 103            EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            141

TABLE 104            EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023–2030 (USD MILLION)                142

TABLE 105            EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            142

TABLE 106            EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            142

TABLE 107            GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040          143

TABLE 108            GERMANY: KEY MACROINDICATORS      144

TABLE 109            GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            144

TABLE 110            GERMANY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            144

TABLE 111            GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            145

TABLE 112            GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            145

TABLE 113            GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            145

TABLE 114            UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 147

TABLE 115            UK: KEY MACROINDICATORS     147

TABLE 116            UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     147

TABLE 117            UK: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            148

TABLE 118            UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            148

TABLE 119            UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                148

TABLE 120            UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            149

TABLE 121            SWEDEN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040          150

TABLE 122            SWEDEN: KEY MACROINDICATORS         150

TABLE 123            SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            150

TABLE 124            SWEDEN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            151

TABLE 125            SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            151

TABLE 126            SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)         151

TABLE 127            SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            152

TABLE 128          FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040       152

TABLE 129            FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     153

TABLE 130            FRANCE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            153

TABLE 131            FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            153

TABLE 132            FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)         154

TABLE 133            FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            154

TABLE 134            SPAIN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     155

TABLE 135            SPAIN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            155

TABLE 136            SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            155

TABLE 137            SPAIN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                156

TABLE 138            SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            156

TABLE 139            ITALY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     157

TABLE 140            ITALY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            157

TABLE 141            ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            157

TABLE 142            ITALY: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                158

TABLE 143            ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            158

TABLE 144            REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            159

TABLE 145            REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            159

TABLE 146            REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            159

TABLE 147            REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            160

TABLE 148            REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)     160

TABLE 149            ASIA PACIFIC: MACROINDICATORS         161

TABLE 150            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            163

TABLE 151            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            163

TABLE 152            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            163

TABLE 153            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            164

TABLE 154            ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            164

TABLE 155            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            164

TABLE 156            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023–2030 (USD MILLION)         165

TABLE 157            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)          165

TABLE 158            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            165

TABLE 159            CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040       166

TABLE 160            CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     167

TABLE 161            CHINA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            167

TABLE 162            CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            167

TABLE 163            CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                168

TABLE 164            CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            168

TABLE 165            JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040       169

TABLE 166            JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     169

TABLE 167            JAPAN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            170

TABLE 168            JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            170

TABLE 169            JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                170

TABLE 170            JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            171

TABLE 171            INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040       172

TABLE 172            INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     172

TABLE 173            INDIA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            172

TABLE 174            INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            173

TABLE 175            INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                173

TABLE 176            INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            173

TABLE 177            REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            174

TABLE 178            REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION)                 175

TABLE 179            REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION)                 175

TABLE 180            REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            175

TABLE 181            REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)     176

TABLE 182            LATIN AMERICA: MACROINDICATORS  176

TABLE 183            LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            177

TABLE 184            LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            177

TABLE 185            LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            177

TABLE 186            LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            178

TABLE 187            LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            178

TABLE 188            LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 178

TABLE 189            LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE,

2023–2030 (USD MILLION)            179

TABLE 190            LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            179

TABLE 191            LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            179

TABLE 192            BRAZIL: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040       180

TABLE 193            BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     180

TABLE 194            BRAZIL: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            181

TABLE 195            BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            181

TABLE 196            BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                181

TABLE 197            BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            182

TABLE 198          MEXICO: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040       182

TABLE 199            MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     183

TABLE 200            MEXICO: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            183

TABLE 201            MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            183

TABLE 202            MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)         184

TABLE 203            MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            184

TABLE 204            REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            185

TABLE 205            REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION)            185

TABLE 206            REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 185

TABLE 207            REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            186

TABLE 208            REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)     186

TABLE 209            MIDDLE EAST & AFRICA: KEY MACROINDICATORS      187

TABLE 210            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            187

TABLE 211            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            188

TABLE 212            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION)                 188

TABLE 213            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION)                 188

TABLE 214            MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            189

TABLE 215            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)     189

TABLE 216            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE,

2023–2030 (USD MILLION)            189

TABLE 217            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            190

TABLE 218            MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER,

2023–2030 (USD MILLION)            190

TABLE 219            GCC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     191

TABLE 220            GCC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,

2023–2030 (USD MILLION)            191

TABLE 221            GCC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,

2023–2030 (USD MILLION)            191

TABLE 222            GCC: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                192

TABLE 223            GCC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)            192

TABLE 224            REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 193

TABLE 225            REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION)            193

TABLE 226            REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 193

TABLE 227            REST OF MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                 194

TABLE 228            REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION)           194

TABLE 229            OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES                195

TABLE 230            DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION 199

TABLE 231            DIGITAL PATHOLOGY MARKET: PRODUCT FOOTPRINT       203

TABLE 232            DIGITAL PATHOLOGY MARKET: APPLICATION FOOTPRINT       204

TABLE 233            DIGITAL PATHOLOGY MARKET: END-USER FOOTPRINT       205

TABLE 234            DIGITAL PATHOLOGY MARKET: REGION FOOTPRINT       206

TABLE 235            DIGITAL PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES  209

TABLE 236            DIGITAL PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS                 210

TABLE 237            DIGITAL PATHOLOGY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022–JUNE 2025             213

TABLE 238            DIGITAL PATHOLOGY MARKET: DEALS, JANUARY 2022–JUNE 2025              214

TABLE 239            DIGITAL PATHOLOGY MARKET: OTHER DEVELOPMENTS,

JANUARY 2022–JUNE 2025              214

TABLE 240            DANAHER CORPORATION: COMPANY OVERVIEW          215

TABLE 241            DANAHER CORPORATION: PRODUCTS OFFERED             216

TABLE 242            DANAHER CORPORATION: DEALS, JANUARY 2022−JUNE 2025                217

TABLE 243            F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW          218

TABLE 244            F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED             219

TABLE 245            HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2022–JUNE 2025              220

TABLE 246            HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–JUNE 2025  220

TABLE 247            SECTRA AB: COMPANY OVERVIEW          222

TABLE 248            SECTRA AB: PRODUCTS OFFERED           223

TABLE 249            SECTRA AB: DEALS, JANUARY 2022–JUNE 2025                 224

TABLE 250            SECTRA AB: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025  226

TABLE 251            HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW          227

TABLE 252            HAMAMATSU PHOTONICS K.K.: PRODUCTS OFFERED             228

TABLE 253            HAMAMATSU PHOTONICS K.K.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025   229

TABLE 254            HAMAMATSU PHOTONICS K.K.: DEALS, JANUARY 2022–JUNE 2025              229

TABLE 255            KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW          231

TABLE 256            KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED             232

TABLE 257            KONINKLIJKE PHILIPS N.V: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025   233

TABLE 258            KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2022−JUNE 2025                233

TABLE 259            AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW          235

TABLE 260            AKOYA BIOSCIENCES INC.: PRODUCTS OFFERED             236

TABLE 261            AKOYA BIOSCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2022–JUNE 2024              237

TABLE 262            FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW   238

TABLE 263            FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED    239

TABLE 264            FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JUNE 2025              240

TABLE 265            HOLOGIC, INC.: COMPANY OVERVIEW  241

TABLE 266            HOLOGIC, INC: PRODUCTS OFFERED    242

TABLE 267            HOLOGIC, INC: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025              243

TABLE 268            3DHISTECH LTD.: COMPANY OVERVIEW                 244

TABLE 269            3DHISTECH LTD.: PRODUCTS OFFERED                 244

TABLE 270            3DHISTECH LTD.: PRODUCT LAUNCHES & ENHANCEMENTS,

JANUARY 2022–JUNE 2024              245

TABLE 271            3DHISTECH LTD.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2024              246

TABLE 272            APOLLO ENTERPRISE IMAGING CORP.: COMPANY OVERVIEW   247

TABLE 273            APOLLO ENTERPRISE IMAGING CORP.: PRODUCTS OFFERED    247

TABLE 274            APOLLO ENTERPRISE IMAGING CORP.: PRODUCT ENHANCEMENTS,

JANUARY 2022–JUNE 2025              248

TABLE 275            APOLLO ENTERPRISE IMAGING CORP.: DEALS, JANUARY 2022–JUNE 2025              248

TABLE 276            XIFIN, INC.: COMPANY OVERVIEW           249

TABLE 277            XIFIN, INC.: PRODUCTS OFFERED            249

TABLE 278            XIFIN, INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025  249

TABLE 279            XIFIN, INC.: DEALS, JANUARY 2022–JUNE 2025                 250

TABLE 280            HURON DIGITAL PATHOLOGY: COMPANY OVERVIEW          251

TABLE 281            HURON DIGITAL PATHOLOGY: PRODUCTS OFFERED             251

TABLE 282            HURON DIGITAL PATHOLOGY: DEALS, JANUARY 2022–JUNE 2025              252

TABLE 283            INDICA LABS: COMPANY OVERVIEW      253

TABLE 284            INDICA LABS: PRODUCTS OFFERED       253

TABLE 285            INDICA LABS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025   254

TABLE 286            INDICA LABS: DEALS, JANUARY 2022–JUNE 2025                 254

TABLE 287            OPTRASCAN, INC.: COMPANY OVERVIEW                 256

TABLE 288            OPTRASCAN, INC.: PRODUCTS OFFERED                 256

TABLE 289            OPTRASCAN, INC.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2022–JUNE 2025              257

TABLE 290            OPTRASCAN, INC.: DEALS, JANUARY 2022–JUNE 2025        257

TABLE 291            GLENCOE SOFTWARE, INC.: COMPANY OVERVIEW          258

TABLE 292            GLENCOE SOFTWARE, INC.: PRODUCTS OFFERED             258

TABLE 293            GLENCOE SOFTWARE, INC.: PRODUCT ENHANCEMENTS,

JANUARY 2022–JUNE 2025              259

TABLE 294            AIFORIA TECHNOLOGIES OY: COMPANY OVERVIEW          260

TABLE 295            AIFORIA TECHNOLOGIES OY: PRODUCTS OFFERED             260

TABLE 296            PAIGE AI, INC.: COMPANY OVERVIEW    262

TABLE 297            PAIGE AI, INC.: PRODUCTS OFFERED     262

TABLE 298            PAIGE AI, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,

JANUARY 2022–JUNE 2025              263

TABLE 299            PAIGE AI, INC.: DEALS, JANUARY 2022–JUNE 2025                 263

TABLE 300            PROSCIA, INC.: COMPANY OVERVIEW    265

TABLE 301            PROSCIA, INC.: PRODUCTS OFFERED     265

TABLE 302            PROSCIA, INC.: PRODUCT ENHANCEMENTS & APPROVALS,

JANUARY 2022–JUNE 2025              266

TABLE 303            PROSCIA, INC.: DEALS, JANUARY 2022–JUNE 2025                 266

TABLE 304            QUEST DIAGNOSTICS: COMPANY OVERVIEW                 268

TABLE 305            KONFOONG BIOTECH INTERNATIONAL CO., LTD.: COMPANY OVERVIEW       269

TABLE 306            MIKROSCAN TECHNOLOGIES, INC.: COMPANY OVERVIEW          270

TABLE 307            MOTIC DIGITAL PATHOLOGY: COMPANY OVERVIEW          271

TABLE 308            KANTERON SYSTEMS: COMPANY OVERVIEW                 272

TABLE 309            MORPHLE LABS INC.: COMPANY OVERVIEW                 272

TABLE 310            EW HEALTHCARE PARTNERS: COMPANY OVERVIEW          273

LIST OF FIGURES

FIGURE 1              DIGITAL PATHOLOGY MARKET                29

FIGURE 2              RESEARCH DESIGN         32

FIGURE 3              PRIMARY SOURCES         35

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE,

DESIGNATION, AND REGION     36

FIGURE 5              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           37

FIGURE 6              MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS            38

FIGURE 7              DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS OF DANAHER CORPORATION                 39

FIGURE 8              BOTTOM-UP APPROACH              40

FIGURE 9              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 41

FIGURE 10            CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DIGITAL PATHOLOGY MARKET (2025–2030)         42

FIGURE 11            DATA TRIANGULATION METHODOLOGY                 44

FIGURE 12            DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)      47

FIGURE 13            DIGITAL PATHOLOGY MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)                48

FIGURE 14            DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)       48

FIGURE 15            DIGITAL PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      49

FIGURE 16            GEOGRAPHIC SNAPSHOT OF DIGITAL PATHOLOGY MARKET  50

FIGURE 17            RISING INCIDENCE OF CANCER AND GROWING ADOPTION OF PATHOLOGY SOLUTIONS FOR ENHANCED LAB EFFICIENCY TO DRIVE MARKET                51

FIGURE 18            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024        52

FIGURE 19            UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD         53

FIGURE 20            ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    54

FIGURE 21            DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES         55

FIGURE 22            GLOBAL CANCER INCIDENCE, 2008−2030                 57

FIGURE 23            FDA-APPROVED PERSONALIZED MEDICINES, 2015−2022            61

FIGURE 24            DIGITAL PATHOLOGY MARKET: VALUE CHAIN ANALYSIS            67

FIGURE 25            DIGITAL PATHOLOGY MARKET: ECOSYSTEM ANALYSIS            68

FIGURE 26            DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS           69

FIGURE 27            EUROPE: IVDR TIMELINE             74

FIGURE 28            JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR

DIGITAL PATHOLOGY PATENTS, 2014–2025         77

FIGURE 29            MAJOR PATENTS FOR DIGITAL PATHOLOGY (2015–2025)          77

FIGURE 30            KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS             82

FIGURE 31            TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS   83

FIGURE 32            RECENT FUNDING OF PLAYERS IN DIGITAL PATHOLOGY MARKET  85

FIGURE 33            NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT       129

FIGURE 34            ASIA PACIFIC: DIGITAL PATHOLOGY MARKET SNAPSHOT          162

FIGURE 35            REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET                197

FIGURE 36            DIGITAL PATHOLOGY MARKET SHARE ANALYSIS            198

FIGURE 37            DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023       201

FIGURE 38            DIGITAL PATHOLOGY MARKET: COMPANY FOOTPRINT       202

FIGURE 39            DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2024              208

FIGURE 40            EV/EBITDA OF KEY VENDORS   211

FIGURE 41            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF DIGITAL PATHOLOGY VENDORS                 211

FIGURE 42            DIGITAL PATHOLOGY MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS   212

FIGURE 43            DANAHER CORPORATION: COMPANY SNAPSHOT (2024)             216

FIGURE 44            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)             219

FIGURE 45            SECTRA AB: COMPANY SNAPSHOT (2024)                 223

FIGURE 46            HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2024)             228

FIGURE 47            KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)             232

FIGURE 48            AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024)             236

FIGURE 49            FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)      239

FIGURE 50            HOLOGIC, INC.: COMPANY SNAPSHOT (2024)                 242

MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 水性バリアコーティング市場 – 2030年までの世界予測 2025-07-03
• 工作機械市場 – 2032年までの世界予測 2025-07-03
• 軟組織修復市場 – 2030年までの世界予測 2025-07-02
• エポキシ樹脂市場 – 2030年までの世界予測 2025-07-02
• スマートガスメーター市場 – 2030年までの世界予測 2025-07-02

MarketsandMarkets  出版レポート一覧